[Form 4] Imunon, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Imunon, Inc. (IMNN) Form 4: Director Donald P. Braun reported two transactions dated 08/04/2025 following the company’s 1-for-15 reverse split completed 07/25/2025.

• Equity grant in lieu of cash fees: 2,040 common shares acquired at the split-adjusted closing price of $9.20, increasing Braun’s direct holdings to 3,747 shares.
• New stock option: right to purchase 250 shares at an exercise price of $9.20; 50% vests immediately, 25% after one year, and the remaining 25% after two years, expiring 08/04/2035.

Post-transaction, Braun also holds 250 options in addition to the common shares. The share acquisition represents payment of board fees in stock rather than cash, signalling alignment with shareholder interests, though the dollar value (<≈ $18.8 k) is modest relative to market capitalization. No sales were disclosed.

Positive

• Director acquired 2,040 shares instead of cash compensation, a vote of confidence and better alignment with shareholders.

Negative

• Recent 1-for-15 reverse split referenced in the filing underlines earlier share-price weakness, though not a new event.

Insights

Equity Research Analyst

TL;DR: Small insider buy plus options; positive alignment but financially immaterial.

The director chose stock compensation, adding 2,040 shares and 250 options at the split-adjusted price of $9.20. While insider purchases often indicate confidence, the cash value is limited (<$20k) and unlikely to move forecasts or valuation. The 1-for-15 reverse split, mentioned for context, suggests prior price pressure but is not part of this filing’s transactions. Overall impact on capital structure and float is negligible.

Corporate Governance Specialist

TL;DR: Governance-friendly equity fee choice; neutral financial impact.

Paying board fees in shares tightens director–shareholder alignment without cash outflow. Vesting schedule of the option encourages medium-term oversight. However, scale is minor and does not alter control dynamics. No red flags in reporting or pricing relative to market close.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Braun Donald P

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2025		A		2,040(1)	A	$9.2	3,747	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.2(2)	08/04/2025		A		250		08/04/2025(3)	08/04/2035	Common Stock	250	$0	250	D

Explanation of Responses:

1. Stock granted in lieu of cash for portion of board fees

2. Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

3. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

Remarks:

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

	/s/ Susan Eylward, Attorney-in-Fact for Donald P. Braun	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IMNN shares did Director Donald P. Braun acquire?

He received 2,040 split-adjusted common shares on 08/04/2025.

What is the exercise price and size of the new IMNN stock option?

Braun obtained an option for 250 shares at an exercise price of $9.20 per share.

How many IMNN shares does Braun hold after the reported transactions?

His direct ownership increased to 3,747 common shares, plus 250 options.

Why did the share count appear reduced compared with prior filings?

Imunon executed a 1-for-15 reverse stock split on 07/25/2025, adjusting share counts and option terms.

Does the filing disclose any insider sales?

No. All reported transactions were acquisitions; no shares or options were sold.